Search Results - "GAVISH, D"

Refine Results
  1. 1

    Does metformin treatment influence bone formation in patients with nonalcoholic fatty liver disease? by Soifer, E, Gavish, D, Shargorodsky, M

    Published in Hormone and metabolic research (01-07-2015)
    “…Antidiabetic drug metformin that improves insulin sensitivity and used in the treatment of nonalcoholic fatty liver disease (NAFLD), may affect the bone…”
    Get more information
    Journal Article
  2. 2
  3. 3

    Adiponectin and vascular properties in obese patients: is it a novel biomarker of early atherosclerosis by Shargorodsky, M, Boaz, M, Goldberg, Y, Matas, Z, Gavish, D, Fux, A, Wolfson, N

    Published in International Journal of Obesity (01-05-2009)
    “…Objectives: Adiponectin is an adipocyte-derived collagen-like protein, highly specific to adipose tissue and may represent an important link between obesity…”
    Get full text
    Journal Article
  4. 4

    Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS by Oz, H, Gavish, D, Hass, A, Shargorodsky, M

    “…Introduction: The renin-angiotensin-aldosterone system (RAAS) has recently been considered as a possible link between bone and vascular disease. The present…”
    Get full text
    Journal Article
  5. 5

    Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women by Shargorodsky, M, Boaz, M, Luckish, A, Matas, Z, Gavish, D, Mashavi, M

    Published in Atherosclerosis (01-06-2009)
    “…Abstract Osteoprotegerin (OPG) appears to represent the molecular link between bone resorption and vascular calcification, and may help to explain the high…”
    Get full text
    Journal Article
  6. 6

    The effect of a rapid weight loss induced by laparoscopic adjustable gastric banding on arterial stiffness, metabolic and inflammatory parameters in patients with morbid obesity by SHARGORODSKY, M, FLEED, A, BOAZ, M, GAVISH, D, ZIMLICHMAN, R

    Published in International Journal of Obesity (01-11-2006)
    “…To determine the effect of drastic weight loss on arterial compliance, inflammatory and metabolic parameters in patients with morbid obesity with and without…”
    Get full text
    Journal Article
  7. 7

    Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma by Shargorodsky, M, Serov, S, Gavish, D, Leibovitz, E, Harpaz, D, Zimlichman, R

    Published in Thyroid (New York, N.Y.) (01-04-2006)
    “…Exogenous subclinical hyperthyroidism, caused by long-term thyrotropin (TSH)-suppressive treatment with levothyroxine (LT(4)), is associated with several…”
    Get more information
    Journal Article
  8. 8

    High dose treatment with angiotensin II receptor blocker in patients with hypertension: Differential effect of tissue protection versus blood pressure lowering by Shargorodsky, M, Hass, E, Boaz, M, Gavish, D, Zimlichman, R

    Published in Atherosclerosis (01-03-2008)
    “…Abstract Aggressive inhibition of renin–angiotensin–aldosterone system may provide the best cardiovascular protection. We examined the effect of different…”
    Get full text
    Journal Article
  9. 9

    Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients by Mashavi, M, Hanah, R, Boaz, M, Gavish, D, Matas, Z, Fux, A, Shargorodsky, M

    Published in Atherosclerosis (01-08-2008)
    “…Abstract Metformin may affect the risk of atherothrombotic disease. However, metformin increases levels of homocysteine (Hcy), considered an independent risk…”
    Get full text
    Journal Article
  10. 10

    Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors by Luckish, A, Cernes, R, Boaz, M, Gavish, D, Matas, Z, Fux, A, Shargorodsky, M

    Published in Bone (New York, N.Y.) (01-08-2008)
    “…Abstract Accumulating evidence suggests that osteoporosis and coronary artery disease have epidemiologic similarities. Moreover, the anti-atherogenic effects…”
    Get full text
    Journal Article
  11. 11

    Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety by Gavish, D., Leibovitz, E., Shapira, I., Rubinstein, A.

    Published in Journal of internal medicine (01-05-2000)
    “… Gavish D, Leibovitz E, Shapira I, Rubinstein A (Wolfson Medical Center, Holon, and Tel Aviv Sourasky Medical Center, Tel Aviv, Israel). Bezafibrate and…”
    Get full text
    Journal Article
  12. 12

    Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study by Shargorodsky, M., Michaelova, K., Boaz, M., Gavish, D., Zimlichman, R.

    Published in Diabetic medicine (01-11-2007)
    “…Aims  Thiazolidinediones may influence the atherogenic process by improving cardiovascular risk factors. The present study was designed to determine the…”
    Get full text
    Journal Article
  13. 13

    HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels by KOSTNER, G. M, GAVISH, D, LEOPOLD, B, BOLZANO, K, WEINTRAUB, M. S, BRESLOW, J. L

    Published in Circulation (New York, N.Y.) (01-11-1989)
    “…Lp(a) is a plasma lipoprotein particle consisting of a plasminogenlike protein [apo(a)] disulfide bonded to the apo B moiety of low-density lipoprotein (LDL)…”
    Get full text
    Journal Article
  14. 14
  15. 15

    The Ashkelon Hypertension Detection and Control Program (AHDC Program): a community approach to reducing cardiovascular mortality by Yosefy, C, Dicker, D, Viskoper, J.R, Tulchinsky, T.H, Ginsberg, G.M, Leibovitz, E, Gavish, D

    Published in Preventive medicine (01-12-2003)
    “…Blood pressure (BP) reduction is crucial in reducing cardiovascular (CV) morbidity and mortality in the community. Subjects aged 20–65 seldom visit the primary…”
    Get full text
    Journal Article
  16. 16

    Plasma Lp(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the Apo(a) gene by GAVISH, D, AZROLAN, N, BRESLOW, J. L

    “…Plasma Lp(a) levels correlate with atherosclerosis susceptibility. This lipoprotein consists of an LDL-like particle attached to a large glycoprotein called…”
    Get full text
    Journal Article
  17. 17

    Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model by AZROLAN, N, GAVISH, D, BRESLOW, J. L

    Published in The Journal of biological chemistry (25-07-1991)
    “…The cynomolgus macaque was used as a model to study lipoprotein(a) (Lp(a)). Antibodies to Lp(a) were used in Ouchterlony and Western blot analysis to show that…”
    Get full text
    Journal Article
  18. 18

    Lipoprotein(a) reduction by N-acetylcysteine by Gavish, D, Breslow, J L

    Published in The Lancet (British edition) (26-01-1991)
    “…Lipoprotein(a), a complex of low-density lipoprotein linked by disulphide bridges with apo(a), is associated with atherosclerotic disease when present at very…”
    Get more information
    Journal Article
  19. 19

    Medical history of hypercholesterolaemia adversely affects the outcome of out-of-hospital cardiopulmonary resuscitation. The ‘Shahal’ experience in Israel by Roth, A, Golovner, M, Gavish, D, Shapira, I, Malov, N, Sender, J, Alroy, I, Kaplinski, E, Laniado, S

    Published in European heart journal (01-05-2000)
    “…Aims To evaluate the impact selected risk factors for cardiac death may have on the success rate in a large cohort of subscribers to ‘SHAHAL’ who were…”
    Get full text
    Journal Article
  20. 20

    Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment by EISENBERG, S, GAVISH, D, OSCHRY, Y, FAINARU, M, DECKELBAUM, R. J

    Published in The Journal of clinical investigation (01-08-1984)
    “…The effects of triglyceridemia on plasma lipoproteins were investigated in 16 hypertriglyceridemic (HTG) subjects (222-2,500 mg/dl) before and after the…”
    Get full text
    Journal Article